Canadian Consensus Recommendations for Predictive Biomarker Testing in Gastric and Gastroesophageal Junction Adenocarcinoma
Christine Brezden‐Masley(Mount Sinai Hospital), Catherine Streutker(University of Toronto), Pierre Fiset(Christie (Canada)), Sara V. Soldera(Hôpital Charles-Le Moyne), Thomas Arnason(Dalhousie University), Gertruda Evaristo(McGill University Health Centre), Brandon S. Sheffield(BC Cancer Agency), Diana Beşliu-Ionescu(University of British Columbia), Justin Bateman(Alberta Hospital Edmonton), Carol C. Cheung(University Health Network), Howard J. Lim(BC Cancer Agency), Martin Borduas(Centre Hospitalier Universitaire de Sherbrooke)
Cited by 5
Related Papers
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes
|JAMA Oncology|2016|375
Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy
|Canadian Journal of Cardiology|2016|234
Accuracy of coding for possible warfarin complications in hospital discharge abstracts
|Thrombosis Research|2005|194
Synthesis of diagnostic quality cancer pathology images by generative adversarial networks
|The Journal of Pathology|2020|123